Dr. Wenjin Wang | Targeted Cancer Therapy | Young Scientist Award

Posted on by Pencis

Dr. Wenjin Wang | Targeted Cancer Therapy | Young Scientist Award

The Chinese University of Hong Kong | China

Author Profile

Scopus

Dr. Wenjin Wang šŸŒŸšŸ”¬

Postdoctoral Researcher | Tumor Photodynamic Therapy Expert | Biomolecular Phase Separation Investigator

Research Interests

  1. Tumor Photodynamic Therapy (PDT) šŸ’”šŸŽÆ
    • Design and synthesis of novel photosensitizers for PDT.
    • Development of tumor-targeted PDT using tumor-responsive AIE (Aggregation-Induced Emission) photosensitizers.
  2. Regulation of Biomolecular Phase Separation šŸ§¬āš›ļø
    • Investigation into the phase separation behaviors of biomolecules like proteins and nucleic acids.
    • Modulation of these processes with chemical molecules to enhance understanding of intracellular organization and function.

Professional Experience

  • Postdoctoral Researcher šŸ¢
    The Chinese University of Hong Kong, Shenzhen (07/2022ā€“Present)

    • Research on bioapplications of AIE materials under Prof. Ben Zhong Tang.
  • Biochemical Engineer šŸ§Ŗ
    Shenzhen BGI Research Institute (10/2017ā€“09/2018)

    • Designed and optimized unnatural nucleotides for sequencing applications.
  • Laboratory Assistant šŸ”¬
    Peking University Shenzhen Graduate School (11/2016ā€“10/2017)

    • Focused on unnatural amino acids and asymmetric carbene O-H bond insertion catalysis by myoglobin proteins.
  • Research Associate šŸ’Š
    Tianjin Institute of Pharmaceutical Research (08/2014ā€“11/2016)

    • Developed new hypoglycemic drugs through innovative designs and research.

Education

  • Ph.D. in Chemical Biology šŸ§«
    Sun Yat-Sen University (09/2018ā€“06/2022)

    • Thesis: Antitumor mechanisms of metal complexes and their regulation on biomolecular phase separation behavior.
  • M.S. in Pharmacy šŸ’Š
    Tianjin Medical University (09/2012ā€“06/2015)

    • Research: Development of SGLT2 inhibitors and hypoglycemic activity evaluation.
  • B.S. in Pharmacy šŸ„
    Tianjin Medical University (09/2008ā€“06/2012)

Grants and Funding šŸ’°šŸ“š

  1. National Natural Science Foundation of China
    • Ruthenium Complexes and Lipid Phase Separation in Antitumor Research (2024ā€“2026, RMB 300K, Principal Investigator).
  2. China Postdoctoral Science Foundation
    • GGT-Activated AIE Photosensitizers for Tumor Photodynamic Therapy (2022ā€“2025, RMB 80K, Principal Investigator).
  3. Shenzhen Medical Research Fund
    • Manipulable Aggregation of AIE Photosensitizers for Enhanced Tumor PDT (2025ā€“2027, RMB 800K, Principal Investigator).
  4. National Natural Science Foundation of China
    • Phase Separation Mechanism of Antitumor Phosphor Metal Complexes (2022ā€“2025, RMB 630K, Major Participant).
  5. Yunnan Province Science and Technology Plan
    • Aggregate Induced Luminescence in Biomass Resources (2024ā€“2026, RMB 2000K, Major Participant).

Awards and Honors šŸ†āœØ

  • Excellent Postdoctoral Doctor (Shenzhen, 12/2023).
  • National Scholarship for Doctoral Students (12/2021).
  • “Fran” Excellent Thesis Scholarship (Second Class, Sun Yat-sen University, 11/2021).
  • Excellent Wall Poster Award (32nd Academic Annual Meeting, Chinese Chemical Society, 04/2021).

Key Contributions šŸ“ˆ

Dr. Wangā€™s groundbreaking research combines innovative photodynamic therapies and the manipulation of biomolecular phase separation, driving advancements in cancer treatment and molecular biology.

šŸ“ŠšŸ”¬NOTABLE PUBLICATION:
  • Title: Multi-Stimuli-Responsive and Cell Membrane Camouflaged Aggregation-Induced Emission Nanogels for Precise Chemo-photothermal Synergistic Therapy of Tumors
    • Authors: Zhang, L.; Wang, Z.; Zhang, R.; … Zhao, Z.; Tang, B.Z.
    • Journal: ACS Nano
    • Year: 2023

 

  • Title: Multi-site isomerization of synergistically regulated stimuli-responsive AIE materials toward multi-level decryption
    • Authors: Zhong, W.; Zhang, J.; Lin, Y.; … Cai, X.-M.; Tang, B.Z.
    • Journal: Chemical Science
    • Year: 2024

 

  • Title: Chromene-based BioAIEgens: ā€˜in-waterā€™ synthesis, regiostructure-dependent fluorescence and ER-specific imaging
    • Authors: Cai, X.-M.; Lin, Y.; Zhang, J.; … Zhao, Z.; Tang, B.Z.
    • Journal: National Science Review
    • Year: 2023

 

  • Title: Natural Acceptor of Coumarin-Isomerized Red-Emissive BioAIEgen for Monitoring CuĀ²āŗ Concentration in Live Cells via FLIM
    • Authors: Cai, X.-M.; Li, S.; Wang, W.-J.; … Zhao, Z.; Tang, B.Z.
    • Journal: Advanced Science
    • Year: 2024

 

  • Title: Room Temperature Phosphorescent Nanofiber Membranes by Bio-Fermentation
    • Authors: Nie, X.; Gong, J.; Ding, Z.; … Qiu, Z.; Tang, B.Z.
    • Journal: Advanced Science
    • Year: 2024

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Posted on by Pencis

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Yueyang Central Hospital | China

AUTHOR PROFILE

ORCID ID

šŸ“šEARLY ACADEMIC PURSUITSĀ 

ZENG QINGJUN completed his Masterā€™s degree at Xiangya Medical College, Central South University, in 2010. This prestigious institution provided a strong foundation in medical education, equipping him with the skills and knowledge necessary for his future in the field of gastrointestinal surgery. His academic training allowed him to develop expertise in complex surgical techniques, laying the groundwork for his career as a clinical specialist in surgery.

āš•ļøPROFESSIONAL ENDEAVORSĀ 

Since July 2010, ZENG QINGJUN has been working in the field of gastrointestinal surgery, focusing on laparoscopic techniques for treating gastric and colorectal cancers. As a chief physician, he plays a pivotal role in leading surgical teams, performing high-risk surgeries, and making critical decisions for patient care. His clinical expertise and skillful handling of over 200 laparoscopic gastric cancer surgeries and 400 laparoscopic colorectal cancer surgeries are testaments to his proficiency in minimally invasive surgical methods. His surgical outcomes have contributed significantly to improving the quality of life for cancer patients and are recognized within the medical community.

šŸ”¬CONTRIBUTIONS AND RESEARCH FOCUS ON GASTROINTESTINAL TUMORS

Dr. ZENG has dedicated much of his professional life to the development and refinement of laparoscopic surgical techniques in the treatment of gastrointestinal cancers. His research is heavily focused on advancing minimally invasive surgery, particularly in the areas of gastric cancer and colorectal cancer. Through clinical trials and innovative methodologies, he has been involved in optimizing surgical procedures to ensure better postoperative recovery, reduced complications, and more efficient treatment pathways for cancer patients.

šŸŒIMPACT AND INFLUENCEĀ 

Dr. ZENG QINGJUN has made an immense impact on the practice of gastrointestinal surgery in China, particularly in the realm of laparoscopic surgery. His innovative approaches and commitment to cutting-edge techniques have influenced both local and national surgical practices. His contribution to gastric and colorectal cancer surgery has improved patient outcomes and has set new standards in the field. As a chief physician, he mentors younger surgeons and shares his expertise, ensuring the continued progress of surgical techniques.

šŸ“‘ACADEMIC CITATIONSĀ 

While detailed citation metrics are not provided, Dr. ZENG’s extensive clinical experience and research endeavors have led to his recognition in academic circles. His focus on laparoscopic techniques and cancer surgery continues to influence current and future generations of surgeons and researchers in the field. His work, particularly in gastric and colorectal cancer, has made notable contributions to medical literature and has been referenced in various academic and clinical studies.

šŸŒ±LEGACY AND FUTURE CONTRIBUTIONSĀ 

Dr. ZENG QINGJUNā€™s career reflects a legacy of excellence in surgical practice and medical innovation. His pioneering work in laparoscopic surgery and cancer treatment has already set the stage for future breakthroughs in the field of gastrointestinal oncology. Looking forward, he is likely to contribute even more significantly to surgical research, possibly expanding his focus to robot-assisted surgeries, postoperative care advancements, and the integration of AI in surgical planning. His mentorship, both locally and nationally, will shape the future of surgical education and the next generation of gastrointestinal surgeons.

šŸ’¼LEADERSHIP IN SURGICAL PRACTICEĀ 

Dr. ZENG continues to hold a significant leadership role in the surgical department at his medical institution. His capacity as chief physician enables him to make high-level decisions in clinical practice, direct surgical teams, and implement best practice guidelines. His strategic leadership in gastrointestinal surgery helps to establish protocols for laparoscopic surgeries, improving surgical outcomes, and pushing the boundaries of traditional approaches.

šŸ”— CONCLUSION

Dr. Zeng Qingjun is a distinguished gastrointestinal surgeon whose work has significantly advanced the field of laparoscopic surgery for gastric and colorectal cancers. With over a decade of experience and hundreds of successful surgeries, his contributions have set new standards in minimally invasive surgical techniques, improving patient outcomes and recovery times. Through his leadership as chief physician, he has not only influenced clinical practices but has also become a mentor to aspiring surgeons, ensuring the continuity of high-quality surgical education.

šŸ“ŠšŸ”¬NOTABLE PUBLICATION:
  • 1. Title: Knockdown of BUB1B Inhibits the Proliferation, Migration, and Invasion of Colorectal Cancer by Regulating the JNK/c-Jun Signaling Pathway
    Authors: Qingjun Zeng, Sanjun Zhang, Linfang He, Qingyan Fu, Li Liao, Linjie Chen, Xiang Ding
    Journal: Cancer Biotherapy and Radiopharmaceuticals
    Year: 2023

    2. Title: Targeting of MAD2L1 by miRā€515ā€5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells
    Authors: Xiang Ding, Qingyan Fu, Weixing Chen, Linjie Chen, Qingjun Zeng, Sanjun Zhang, Linfang He
    Journal: Cell Biology International
    Year: 2022

Dr. Jun He | Stem Cell Therapy | Best Researcher Award

Posted on by Pencis

Dr. Jun He | Stem Cell Therapy | Best Researcher Award

The First Affiliated Hospital of Soochow University |Ā  China

Author Profile

Scopus

Dr. Jun He appears to be a highly suitable candidate for the Research for Community Impact Award based on several key factors:

Extensive Professional Experience:

  • Leadership: Dr. He has been the Director of the HLA typing laboratory at the Jiangsu Institute of Hematology since 2010. This role indicates a significant leadership position within an influential research institution.
  • Long-term Commitment: Dr. He has held continuous positions of increasing responsibility at the same institution since 1985, showcasing dedication and consistent contribution to his field.

Educational Background:

  • Dr. He has a robust educational foundation in medicine, with both an M.D. and a B.S. from prestigious institutions in China (Soochow University and Suzhou Medical College).

Impactful Research:

  • Publication Record: Dr. He has published extensively in reputable peer-reviewed journals, with 33 listed publications. These papers cover critical aspects of HLA typing, stem cell transplantation, immunogenetics, and related fields, demonstrating significant contributions to medical science and community health.
  • Research Focus: His research on the genetic loci of HLA, KIRs, and their impact on transplantation outcomes is crucial for improving the success rates and safety of hematopoietic stem cell transplants, a vital area for many patients with hematological malignancies.

Professional Recognition and Membership:

  • Council Memberships: Dr. He has served as a Council Member for both the Experts Committee of the China Marrow Donor Program and The Chinese Medical Society of Organ Transplantation, indicating peer recognition and trust in his expertise.
  • International Membership: His membership in the American Society of Histocompatibility and Immunogenetics shows his engagement with the global scientific community.

Community Impact:

  • Marrow Donor Program: His long-term involvement with the China Marrow Donor Program reflects his commitment to enhancing donor registries and improving transplantation outcomes, directly benefiting patients and the broader community.
  • Training and Mentorship: As a Doctoral Supervisor, Dr. He plays a significant role in training the next generation of medical professionals and researchers, amplifying his impact on community health.

Innovative Research Contributions:

  • NGS and mNGS: His recent work using next-generation sequencing (NGS) and metagenomic NGS for pathogen identification demonstrates his engagement with cutting-edge technologies to improve clinical decision-making and patient outcomes.

In conclusion, Dr. Jun Heā€™s distinguished career, significant research contributions, leadership roles, and dedication to community health make him a highly deserving candidate for the Research for Community Impact Award.

šŸ“ŠšŸ”¬Notable Publication:

    • Authors: Xu, J., Zhou, P., Liu, J., Ma, Y., He, J.
    • Journal: Infectious Diseases and Therapy
    • Year: 2023

 

    • Authors: Jiang, X., Yuan, X., Li, Y., Bao, X., He, J.
    • Journal: HLA
    • Year: 2023

 

    • Authors: Wang, L., Ji, K., Chen, L., Wu, X., He, J.
    • Journal: Frontiers in Immunology
    • Year: 2022

 

    • Authors: Zhou, S., Ma, X., Ma, C., Wu, X., Qin, S.
    • Journal: Bone Marrow Transplantation
    • Year: 2023

 

    • Authors: Cheng, Y., He, J., Zuo, B., He, Y.
    • Journal: Discover Oncology
    • Year: 2024

Dr. Lei Xia | Theranostics | Best Researcher Award

Posted on by Pencis

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |Ā  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD šŸ§¬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
šŸ“ž Phone: 18811177191
āœ‰ļø Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes šŸ©»
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes šŸ§«
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes šŸ§Ŗ
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) šŸŒŸ
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) šŸŒŸ
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) šŸŒŸ
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund šŸŒŸ
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund šŸŒŸ
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital šŸŒŸ
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund šŸŒŸ
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

šŸ“ŠšŸ”¬Notable Publication:

 

 

 

 

Prof Shengping Hou |Ā Immunotherapy | Best Researcher Award

Posted on by Pencis

Prof Shengping Hou | Immunotherapy | Best Researcher Award

Beijing Tongren Hospital, Capital Medical University | China

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

Shengping Hou, Ph.D., began his academic journey at Sun Yat-sen University in China, where he obtained his Ph.D. in Ocular Immunology in 2009. His doctoral research laid the foundation for his future contributions to ocular immunology, particularly focusing on the genetic aspects of ocular diseases. Following his Ph.D., Dr. Hou furthered his expertise with a postdoctoral fellowship at the University of California, San Francisco, specializing in Ocular Stem Cell Biology, which he completed in 2016.

PROFESSIONAL ENDEAVORS

Dr. Hou’s professional career commenced at The First Affiliated Hospital of Chongqing Medical University, where he served as an Associate Professor from 2009 to 2015. He was later promoted to Professor, a position he held until 2023. During his tenure, he was also a key figure at the Chongqing Key Laboratory of Ophthalmology. In 2023, Dr. Hou transitioned to Beijing Tongren Hospital, where he now serves as the Director of the Beijing Institute of Ophthalmology and continues his professorship at Capital Medical University.

CONTRIBUTIONS AND RESEARCH FOCUS ON IMMUNOTHERAPY

Dr. Hou’s research has primarily centered on the genetic and immunological underpinnings of ocular diseases, particularly uveitis and Behcetā€™s disease. His work has involved extensive genetic studies, including the investigation of VKH syndrome and the role of complement component 4 copy number variants in ocular pathogenesis. His notable projects have been consistently supported by grants from the National Natural Science Foundation and other key R&D initiatives in China.

IMPACT AND INFLUENCE

Dr. Hou’s contributions have earned him significant recognition in the scientific community. He has been honored with several prestigious awards, including the First Prize for Achievement in Science and Technology from both Chongqing and the Chinese Health Ministry. His research findings have been widely disseminated through invited lectures and presentations at major international conferences, enhancing the understanding of genetic influences in ocular diseases.

ACADEMIC CITATIONS

Throughout his career, Dr. Hou has been an active member of the Chinese Ocular Immunology Society and has served as an ad hoc reviewer for several high-impact journals such as Nature Reviews Rheumatology, Advanced Science, and eBioMedicine. His work has been extensively cited by peers, reflecting the significant impact of his research on the field of ocular immunology.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Hou’s legacy in the field of ophthalmology is marked by his dedication to uncovering the genetic mechanisms underlying ocular diseases. As the Director of the Beijing Institute of Ophthalmology, he continues to lead groundbreaking research and mentor the next generation of scientists. His future contributions are poised to further advance the understanding and treatment of ocular conditions, solidifying his status as a leading figure in ophthalmic research.

NOTABLE PUBLICATION:

Citation: 36Ā  Ā  Ā  Ā  Ā Year: 2023

Citation: 01Ā  Ā  Ā  Ā  Year: 2023

Cancer Drugs and Vaccines

Posted on by Pencis

Cancer Drugs and Vaccines

Introduction: Cancer Drugs and Vaccines are at the forefront of oncology research and treatment, offering promising solutions in the fight against cancer. These innovative therapies aim to improve patient outcomes, enhance survival rates, and provide hope for individuals battling this devastating disease.

Subtopics in Cancer Drugs and Vaccines:

Immunotherapy in Cancer Treatment: Immunotherapy harnesses the power of the immune system to target and destroy cancer cells. Explore the latest developments in checkpoint inhibitors, CAR-T cell therapy, and immune checkpoint blockade.

Targeted Therapies: Targeted cancer drugs are designed to specifically target cancer cells with minimal damage to healthy tissues. Delve into the mechanisms and effectiveness of these precision therapies.

Vaccine-Based Approaches: Investigate the role of cancer vaccines in preventing or treating various types of cancer. Discover the development and clinical trials of vaccines that stimulate the immune system to recognize and combat cancer cells.

Combination Therapies: Combinatorial approaches involving a mix of drugs, vaccines, and other treatments are gaining traction. Explore how these synergistic combinations are revolutionizing cancer care.

Personalized Medicine: Learn about the concept of tailoring cancer treatments to individual patients based on their genetic and molecular profiles. Explore the advancements in genomic medicine and its impact on cancer drug development.

Resistance Mechanisms: Understand the challenges posed by drug resistance in cancer treatment and how researchers are addressing these issues through innovative strategies.

Emerging Biomarkers: Discover the latest biomarkers used in cancer diagnosis, prognosis, and treatment selection, paving the way for more personalized and effective therapies.

Clinical Trials and Regulatory Challenges: Examine the critical role of clinical trials in evaluating the safety and efficacy of cancer drugs and vaccines, along with the regulatory processes that govern their approval.

Future Trends in Cancer Therapeutics: Explore the cutting-edge technologies and trends shaping the future of cancer treatment, from nanomedicine to gene editing and beyond.

Patient Perspectives and Support: Consider the holistic approach to cancer care, including patient support systems, psychosocial aspects, and quality of life improvements alongside drug and vaccine development.

Medical Oncology

Posted on by Pencis

Medical Oncology

Introduction to Medical Oncology: Medical Oncology is a specialized branch of medicine dedicated to the diagnosis, treatment, and management of cancer. This field plays a pivotal role in improving the lives of cancer patients through various treatment modalities and cutting-edge research. Within the realm of Medical Oncology, several key subtopics are essential for understanding and addressing the complexities of cancer care:

Chemotherapy and Targeted Therapies: Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, while targeted therapies focus on specific molecular abnormalities within cancer cells. Understanding these treatment options is crucial for medical oncologists to tailor therapies for individual patients.

Immunotherapy: Immunotherapy harnesses the body’s immune system to combat cancer. This groundbreaking approach has revolutionized cancer treatment by enhancing the body’s natural defenses against cancer cells.

Precision Medicine: Precision medicine in oncology involves customizing treatment plans based on a patient’s unique genetic and molecular profile. It allows for more personalized and effective cancer treatments, minimizing side effects.

Palliative Care: Palliative care in Medical Oncology is vital for improving the quality of life for cancer patients. It focuses on symptom management, pain relief, and emotional support to enhance patients’ overall well-being.

Clinical Trials and Research: Ongoing research and clinical trials are at the forefront of Medical Oncology. Investigating new treatments, therapies, and breakthroughs in cancer care is essential for improving patient outcomes and advancing the field.

These subtopics illustrate the multidimensional nature of Medical Oncology, where a comprehensive approach is taken to address the complexities of cancer treatment and patient care.